India Pharma Outlook Team | Monday, 22 September 2025
Noida-based Jubilant Pharma Limited has shared the news that its wholly-owned subsidiary, Jubilant Pharma Limited, has wrapped up a Post-marketing Adverse Drug Experience (PADE) inspection by the United States Food and Drug Administration (USFDA) with a successful outcome at its step-down subsidiary, Jubilant Cadista Pharmaceuticals Inc., USA.
The visit was ended with no notices, thus highlighting the company’s commitment to quality, safety, and regulatory compliance. “This result is a strong signal of the pharmaceutical company’s determination to achieve, sustain, and surpass worldwide norms of quality in all of its facilities,” the company stated.
Jubilant Pharma Limited of Singapore is a vertically integrated global pharmaceutical company with a broad portfolio and strong presence in regulated markets. The scope of its business covers the production and supply of radiopharmaceuticals, which are the subject of a network of 45 radiopharmacies in the USA, besides allergy immunotherapy products, contract manufacturing of sterile injectables and non-sterile products, and solid dosage formulations.
Also Read: QIAGEN, APAGE Host Asia GI Consensus on Molecular Testing
Jubilant Pharma is able to cater to the needs of its clients from the United States, the European Union, and other international markets through several high-end facilities. The company, in particular, makes a point that the consistency of its regulatory performance record is one of the major factors which contribute to the culture of compliance and the capacity to meet demanding international standards.
The success of this inspection not only provides a positive signal to Jubilant’s global regulator network but also facilitates its branding as a reliable partner in the supply of quality and safety pharmaceutical products to the patients all over the world.
